CKD-498
CKD-498 is in Phase 2 for female pattern hair loss, developed by Chong Kun Dang Pharmaceutical.
An undisclosed Chong Kun Dang candidate at phase 2 in women with androgenetic alopecia.
Nothing new since Jun 2024
- Developed by
- Chong Kun Dang Pharmaceutical
- Current phase
- Phase 2
- Mechanism
- Undisclosed
- Indications
- Female pattern hair loss
- Last public activity
- June 2024
- Copy last reviewed
- August 2026
- Record confidence
- Low
Tests whether it works, at what dose, in a few hundred people.
The sponsor has not said how it is supposed to work.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
The same sponsor's second hair-loss programme in this register, aimed at women where CKD-843 is aimed at men. Three dose arms in one study; composition undisclosed.
Development history
- Phase 2
First Phase 2 trial on record: NCT05677438 — A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
Chong Kun Dang Pharmaceutical · n=121 · December 2022
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
Related programmes
Other programmes in the register with the same approach.
Cite this page
Hair Pipeline, "CKD-498 — development record", hairpipeline.com/pipeline/ckd-498